Teva Pharmaceutical Industries Stock Price, Forecast & Analysis (NYSE:TEVA)

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) released its quarterly earnings data on Thursday, November, 7th. The company reported $0.56 earnings per share for the quarter, missing analysts' consensus estimates of $0.58 by $0.02. The business earned $4.26 billion during the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. View Teva Pharmaceutical Industries' Earnings History.

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries updated its FY19 earnings guidance on Thursday, November, 7th. The company provided earnings per share (EPS) guidance of $2.30-2.50 for the period, compared to the Thomson Reuters consensus estimate of $2.38. The company issued revenue guidance of $17.2-17.4 billion, compared to the consensus revenue estimate of $17.17 billion.

24 analysts have issued 1 year target prices for Teva Pharmaceutical Industries' shares. Their forecasts range from $6.00 to $20.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $10.23 in the next year. This suggests a possible upside of 0.3% from the stock's current price. View Analyst Price Targets for Teva Pharmaceutical Industries.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 4 sell ratings, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.

Headlines about TEVA stock have trended somewhat positive on Sunday, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the stock's share price in the immediate future. View News Stories for Teva Pharmaceutical Industries.

Some companies that are related to Teva Pharmaceutical Industries include Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF) and Elanco Animal Health (ELAN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Gilead Sciences (GILD), Cisco Systems (CSCO) and CVS Health (CVS).

Teva Pharmaceutical Industries' stock is owned by many different of institutional and retail investors. Top institutional investors include Commerzbank Aktiengesellschaft FI (0.80%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.49%), Sumitomo Mitsui Trust Holdings Inc. (0.37%), Beck Mack & Oliver LLC (0.22%), Strs Ohio (0.14%) and Great West Life Assurance Co. Can (0.05%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone, Sol J Barer and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

TEVA stock was sold by a variety of institutional investors in the last quarter, including Conning Inc., Cacti Asset Management LLC, Strs Ohio, Great West Life Assurance Co. Can, Janney Montgomery Scott LLC, SOL Capital Management CO, Sumitomo Mitsui Trust Holdings Inc. and First Allied Advisory Services Inc.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Luzich Partners Llc, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

TEVA stock was acquired by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Beck Mack & Oliver LLC, Diamond Hill Capital Management Inc., Daiwa Securities Group Inc., Dynamic Capital Management Ltd, Cetera Advisors LLC and IFM Investors Pty Ltd. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone, Sol J Barer and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TEVA stock can currently be purchased for approximately $10.20.

Teva Pharmaceutical Industries has a market capitalization of $11.14 billion and generates $18.85 billion in revenue each year. The company earns $-2,150,000,000.00 in net income (profit) each year or $2.80 on an earnings per share basis. Teva Pharmaceutical Industries employs 42,535 workers across the globe.View Additional Information About Teva Pharmaceutical Industries.

The official website for Teva Pharmaceutical Industries is http://www.tevapharm.com/.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]